PBE Fact Sheet: Invesco Biotechnology & Genome ETF
Share
$92.59
close, Nov 20, 2026
Over the year to Nov 19, 2026, PBE returned +22.8% in total and charged 0.59% a year.
- 1-year total return
- +20.1%
- to Nov 20, 2026
- Expense ratio
- 0.59%
- a year
- Net assets
- $418m
- on Nov 19, 2026
- Net flow, last 5 trading days
- +$24k
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
PBE $12,280 +22.8% · IVV $10,925 +9.2% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−7.0%
3 months−5.1%
Year to date+13.9%
1 year+20.1%
3 years+68.0%
5 years+29.0%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Biogen Inc5.86%
Gilead Sciences Inc5.86%
Regeneron Pharmaceuticals Inc5.79%
Royalty Pharma PLC5.73%
Amgen Inc5.19%
Vertex Pharmaceuticals Inc4.93%
Illumina Inc4.67%
Natera Inc4.50%
Vericel Corp3.85%
Moderna Inc3.58%
PBE top ten by weight, 49.9% of the fund, of its 31 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 31 stocks in biotech, 34% of its weight in S&P 500 companies · First traded Jun 23, 2005 · Benchmark Its own holdings, as of Nov 19, 2026